{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:22:57Z","timestamp":1792606977634,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40262-017-0619-0","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T11:25:55Z","timestamp":1511954755000},"page":"687-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Antibody\u2013Drug Conjugates: Pharmacokinetic\/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned"],"prefix":"10.1007","volume":"57","author":[{"given":"William D.","family":"Hedrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer E.","family":"Fandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam M.","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"issue":"4","key":"619_CR1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"C Fitzmaurice","year":"2015","unstructured":"Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505\u201327.","journal-title":"JAMA Oncol"},{"issue":"21","key":"619_CR2","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643\u201353.","journal-title":"Cancer Res"},{"issue":"11","key":"619_CR3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp048021","volume":"350","author":"RS Schwartz","year":"2004","unstructured":"Schwartz RS. Paul Ehrlich\u2019s magic bullets. N Engl J Med. 2004;350(11):1079\u201380.","journal-title":"N Engl J Med"},{"issue":"16","key":"619_CR4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM197804202981610","volume":"298","author":"VT DeVita Jr","year":"1978","unstructured":"DeVita VT Jr. The evolution of therapeutic research in cancer. N Engl J Med. 1978;298(16):907\u201310.","journal-title":"N Engl J Med"},{"key":"619_CR5","first-page":"1827","volume":"36","author":"IH Plenderleith","year":"1990","unstructured":"Plenderleith IH. Treating the treatment: toxicity of cancer chemotherapy. Can Fam Physician. 1990;36:1827\u201330.","journal-title":"Can Fam Physician"},{"issue":"5","key":"619_CR6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.smim.2008.07.001","volume":"20","author":"A Schietinger","year":"2008","unstructured":"Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol. 2008;20(5):276\u201385.","journal-title":"Semin Immunol"},{"issue":"5517","key":"619_CR7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137.","journal-title":"Nature"},{"issue":"9","key":"619_CR8","first-page":"3147","volume":"40","author":"LM Nadler","year":"1980","unstructured":"Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40(9):3147\u201354.","journal-title":"Cancer Res"},{"issue":"1","key":"619_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V59.1.1.1","volume":"59","author":"J Ritz","year":"1982","unstructured":"Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 1982;59(1):1\u201311.","journal-title":"Blood"},{"issue":"1","key":"619_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","volume":"324","author":"M Berger","year":"2002","unstructured":"Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324(1):14\u201330.","journal-title":"Am J Med Sci"},{"issue":"4","key":"619_CR11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","volume":"3","author":"JK Liu","year":"2014","unstructured":"Liu JK. The history of monoclonal antibody development: progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113\u20136.","journal-title":"Ann Med Surg (Lond)"},{"issue":"12 Pt 1","key":"619_CR12","first-page":"6489","volume":"46","author":"NS Courtenay-Luck","year":"1986","unstructured":"Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46(12 Pt 1):6489\u201393.","journal-title":"Cancer Res"},{"issue":"17","key":"619_CR13","first-page":"3905","volume":"58","author":"LS Zuckier","year":"1998","unstructured":"Zuckier LS, Chang CJ, Scharff MD, Morrison SL. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res. 1998;58(17):3905\u20138.","journal-title":"Cancer Res"},{"issue":"25","key":"619_CR14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"7","key":"619_CR15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"16","key":"619_CR16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"},{"issue":"12","key":"619_CR17","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563\u201371.","journal-title":"J Rheumatol"},{"issue":"1","key":"619_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","volume":"21","author":"L Ducry","year":"2010","unstructured":"Ducry L, Stump B. Antibody\u2013drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5\u201313.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"619_CR19","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","volume":"66","author":"YV Kovtun","year":"2006","unstructured":"Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody\u2013drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214\u201321.","journal-title":"Cancer Res"},{"issue":"2","key":"619_CR20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun YV, Goldmacher VS. Cell killing by antibody\u2013drug conjugates. Cancer Lett. 2007;255(2):232\u201340.","journal-title":"Cancer Lett"},{"issue":"6","key":"619_CR21","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody\u2013maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528\u201337.","journal-title":"Cancer Res"},{"issue":"12","key":"619_CR22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody\u2013drug conjugates. Mol Cancer Ther. 2016;15(12):2825\u201334.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"619_CR23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U. Antibody\u2013drug conjugates: an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362\u20137.","journal-title":"Br J Cancer"},{"key":"619_CR24","unstructured":"FDA news release. FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia. 2017. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm572131.htm . Accessed 30 Aug 2017."},{"issue":"11","key":"619_CR25","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645\u201368.","journal-title":"J Pharm Sci"},{"key":"619_CR26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-62703-541-5_7","volume":"1045","author":"K Lin","year":"2013","unstructured":"Lin K, Tibbitts J, Shen BQ. Pharmacokinetics and ADME characterizations of antibody\u2013drug conjugates. Methods Mol Biol. 2013;1045:117\u201331.","journal-title":"Methods Mol Biol"},{"issue":"9","key":"619_CR27","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1007\/s11095-012-0800-y","volume":"29","author":"K Lin","year":"2012","unstructured":"Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29(9):2354\u201366.","journal-title":"Pharm Res"},{"issue":"3","key":"619_CR28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1208\/s12248-015-9738-4","volume":"17","author":"GG Bornstein","year":"2015","unstructured":"Bornstein GG. Antibody drug conjugates: preclinical considerations. AAPS J. 2015;17(3):525\u201334.","journal-title":"AAPS J"},{"issue":"11","key":"619_CR29","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","volume":"32","author":"AV Kamath","year":"2015","unstructured":"Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res. 2015;32(11):3470\u20139.","journal-title":"Pharm Res"},{"issue":"4","key":"619_CR30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody\u2013drug conjugates. MAbs. 2016;8(4):659\u201371.","journal-title":"MAbs"},{"issue":"3","key":"619_CR31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1078155212464021","volume":"19","author":"AA Baxley","year":"2013","unstructured":"Baxley AA, Kumm DE, Bishop CB, Medina PJ, Holter-Chakrabarty J. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract. 2013;19(3):279\u201383.","journal-title":"J Oncol Pharm Pract"},{"issue":"13","key":"619_CR32","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2146\/ajhp060612","volume":"64","author":"A Hanbali","year":"2007","unstructured":"Hanbali A, Wollner I, Neme K, Ulreich C. Fatal hypersensitivity reaction to gemtuzumab ozogamicin associated with platelet transfusion. Am J Health Syst Pharm. 2007;64(13):1401\u20132.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"619_CR33","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"619_CR34","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198\u2013208.","journal-title":"Blood"},{"issue":"24","key":"619_CR35","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854\u201360.","journal-title":"Blood"},{"issue":"22","key":"619_CR36","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"S Petersdorf","year":"2009","unstructured":"Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 2009;114(22):790.","journal-title":"Blood"},{"issue":"9","key":"619_CR37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bmt.1703242","volume":"28","author":"DK Tack","year":"2001","unstructured":"Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant. 2001;28(9):895\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"619_CR38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/14737140.2016.1162099","volume":"16","author":"J Kell","year":"2016","unstructured":"Kell J. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia. Expert Rev Anticancer Ther. 2016;16(4):377\u201382.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"619_CR39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/00912700122012751","volume":"41","author":"JA Dowell","year":"2001","unstructured":"Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41(11):1206\u201314.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"619_CR40","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.21.15.1175.33890","volume":"21","author":"JM Korth-Bradley","year":"2001","unstructured":"Korth-Bradley JM, Dowell JA, King SP, Liu H, Berger MS, Mylotarg Study Group. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy. 2001;21(10):1175\u201380.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"619_CR41","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0091270004267595","volume":"44","author":"M Buckwalter","year":"2004","unstructured":"Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44(8):873\u201380.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"619_CR42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12185-009-0298-1","volume":"89","author":"Y Kobayashi","year":"2009","unstructured":"Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, et al. Phase I\/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol. 2009;89(4):460\u20139.","journal-title":"Int J Hematol"},{"issue":"7","key":"619_CR43","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310\u20134.","journal-title":"Blood"},{"issue":"9","key":"619_CR44","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986\u201396.","journal-title":"Lancet Oncol"},{"issue":"9825","key":"619_CR45","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"1","key":"619_CR46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","volume":"18","author":"MA Fanale","year":"2012","unstructured":"Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248\u201355.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"619_CR47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643\u201359.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"619_CR48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2 Pt 1","key":"619_CR49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","volume":"11","author":"RJ Sanderson","year":"2005","unstructured":"Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843\u201352.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"619_CR50","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"619_CR51","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody\u2013drug conjugate. Clin Cancer Res. 2010;16(3):888\u201397.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"619_CR52","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861\u201371.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"619_CR53","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421\u201334.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"619_CR54","first-page":"57","volume":"29","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57\u201361.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"619_CR55","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365.","journal-title":"Blood"},{"issue":"19","key":"619_CR56","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med"},{"issue":"26","key":"619_CR57","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/sim.3720","volume":"28","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Kosorok MR, Zeng D. Reinforcement learning design for cancer clinical trials. Stat Med. 2009;28(26):3294\u2013315.","journal-title":"Stat Med"},{"issue":"5","key":"619_CR58","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-014-2561-2","volume":"74","author":"R Wada","year":"2014","unstructured":"Wada R, Erickson HK, Lewis Phillips GD, Provenzano CA, Leipold DD, Mai E, et al. Mechanistic pharmacokinetic\/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother Pharmacol. 2014;74(5):969\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"619_CR59","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4155\/bio.13.76","volume":"5","author":"D Lu","year":"2013","unstructured":"Lu D, Sahasranaman S, Zhang Y, Girish S. Strategies to address drug interaction potential for antibody\u2013drug conjugates in clinical development. Bioanalysis. 2013;5(9):1115\u201330.","journal-title":"Bioanalysis"},{"issue":"1","key":"619_CR60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40262-014-0182-x","volume":"54","author":"Y Chen","year":"2015","unstructured":"Chen Y, Samineni D, Mukadam S, Wong H, Shen BQ, Lu D, et al. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody\u2013drug conjugates. Clin Pharmacokinet. 2015;54(1):81\u201393.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"619_CR61","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00280-016-3180-x","volume":"78","author":"JE Flerlage","year":"2016","unstructured":"Flerlage JE, Metzger ML, Wu J, Panetta JC. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma. Cancer Chemother Pharmacol. 2016;78(6):1217\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"619_CR62","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","volume":"82","author":"B Zhao","year":"2016","unstructured":"Zhao B, Chen R, O\u2019Connor OA, Gopal AK, Ramchandren R, Goy A, et al. Brentuximab vedotin, an antibody\u2013drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol. 2016;82(3):696\u2013705.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"619_CR63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-014-2500-2","volume":"74","author":"D Lu","year":"2014","unstructured":"Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, et al. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody\u2013drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014;74(2):399\u2013410.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"619_CR64","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","volume":"69","author":"S Girish","year":"2012","unstructured":"Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody\u2013drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"619_CR65","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","volume":"75","author":"KJ Hamblett","year":"2015","unstructured":"Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res. 2015;75(24):5329\u201340.","journal-title":"Cancer Res"},{"issue":"3","key":"619_CR66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10928-010-9156-2","volume":"37","author":"NL Jumbe","year":"2010","unstructured":"Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 2010;37(3):221\u201342.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"619_CR67","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","volume":"18","author":"C Cilliers","year":"2016","unstructured":"Cilliers C, Guo H, Liao J, Christodolu N, Thurber GM. Multiscale modeling of antibody\u2013drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 2016;18(5):1117\u201330.","journal-title":"AAPS J"},{"issue":"16","key":"619_CR68","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","volume":"28","author":"IE Krop","year":"2010","unstructured":"Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody\u2013drug conjugate, given every 3\u00a0weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698\u2013704.","journal-title":"J Clin Oncol"},{"issue":"4","key":"619_CR69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-005-1026-z","volume":"56","author":"R Bruno","year":"2005","unstructured":"Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005;56(4):361\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"619_CR70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/hyu160","volume":"45","author":"H Yamamoto","year":"2015","unstructured":"Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, et al. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. Jpn J Clin Oncol. 2015;45(1):12\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"23","key":"619_CR71","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","volume":"118","author":"M Beeram","year":"2012","unstructured":"Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118(23):5733\u201340.","journal-title":"Cancer"},{"issue":"4","key":"619_CR72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398\u2013405.","journal-title":"J Clin Oncol"},{"issue":"2","key":"619_CR73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE Study. J Clin Oncol. 2017;35(2):141\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"619_CR74","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-016-3099-2","volume":"78","author":"C Li","year":"2016","unstructured":"Li C, Wang B, Lu D, Jin JY, Gao Y, Matsunaga K, et al. Ethnic sensitivity assessment of the antibody\u2013drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. Cancer Chemother Pharmacol. 2016;78(3):547\u201358.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"619_CR75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00280-012-1934-7","volume":"70","author":"BC Bender","year":"2012","unstructured":"Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, et al. A population pharmacokinetic\/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2012;70(4):591\u2013601.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"619_CR76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2012.153","volume":"92","author":"VL Chudasama","year":"2012","unstructured":"Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012;92(4):520\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"619_CR77","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1208\/s12248-016-9904-3","volume":"18","author":"AP Singh","year":"2016","unstructured":"Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, et al. Evolution of antibody\u2013drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1). AAPS J. 2016;18(4):861\u201375.","journal-title":"AAPS J"},{"issue":"4","key":"619_CR78","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1208\/s12248-017-0071-y","volume":"19","author":"AP Singh","year":"2017","unstructured":"Singh AP, Shah DK. Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody\u2013drug conjugates: a case study with trastuzumab emtansine (T-DM1). AAPS J. 2017;19(4):1054\u201370.","journal-title":"AAPS J"},{"issue":"5","key":"619_CR79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/2040620715596715","volume":"6","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253\u201361.","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"619_CR80","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"11","key":"619_CR81","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"JF Dijoseph","year":"2007","unstructured":"Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240\u20135.","journal-title":"Leukemia"},{"issue":"11","key":"619_CR82","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood.V108.11.2711.2711","volume":"108","author":"L Fayad","year":"2006","unstructured":"Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E, et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood. 2006;108(11):2711.","journal-title":"Blood"},{"issue":"11","key":"619_CR83","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V112.11.266.266","volume":"112","author":"L Fayad","year":"2008","unstructured":"Fayad L, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, et al. Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1\/2 study. Blood. 2008;112(11):266.","journal-title":"Blood."},{"issue":"12","key":"619_CR84","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085\u201393.","journal-title":"J Clin Oncol"},{"issue":"15","key":"619_CR85","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728\u201336.","journal-title":"Cancer"},{"issue":"8","key":"619_CR86","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/j.1349-7006.2010.01601.x","volume":"101","author":"M Ogura","year":"2010","unstructured":"Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840\u20135.","journal-title":"Cancer Sci"},{"issue":"5","key":"619_CR87","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","volume":"103","author":"M Ogura","year":"2012","unstructured":"Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933\u20138.","journal-title":"Cancer Sci"},{"issue":"5","key":"619_CR88","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","volume":"31","author":"L Fayad","year":"2013","unstructured":"Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573\u201383.","journal-title":"J Clin Oncol"},{"issue":"5","key":"619_CR89","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1208\/s12248-016-9929-7","volume":"18","author":"AM Betts","year":"2016","unstructured":"Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, et al. Preclinical to clinical translation of antibody\u2013drug conjugates using PK\/PD modeling: a retrospective analysis of inotuzumab ozogamicin. AAPS J. 2016;18(5):1101\u201316.","journal-title":"AAPS J"},{"issue":"28","key":"619_CR90","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137\u201343.","journal-title":"J Clin Oncol"},{"issue":"5","key":"619_CR91","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jjco\/hyw013","volume":"46","author":"M Kashiwaba","year":"2016","unstructured":"Kashiwaba M, Ito Y, Takao S, Doihara H, Rai Y, Kanatani K, et al. A multicenter phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. Jpn J Clin Oncol. 2016;46(5):407\u201314.","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"619_CR92","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V106.11.230.230","volume":"106","author":"A Advani","year":"2005","unstructured":"Advani A, Gin\u00e9 E, Gisselbrecht C, Rohatiner A, Rosen S, Smith M, et al. Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin\u2019s lymphoma (NHL). Blood. 2005;106(11):230.","journal-title":"Blood"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0619-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T12:58:30Z","timestamp":1660049910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0619-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0619-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,29]]}}}